《新股表現》昭衍新藥(06127.HK)暗盤低開6%報142元
根據輝立交易平台顯示,明天掛牌的昭衍新藥(06127.HK)暗盤低開6%報142元欠承接,最低見138.2元,造139.1元,較上市價151元,低7.9%,成交8.2萬股。
昭衍新藥是內地專門從事新藥藥理毒理學研究及專注於藥物非臨床安全性評價領先合同研究組織,並正擴展以提供涵蓋藥物研發服務鏈上藥物發現、臨床前和臨床試驗階段綜合服務。是次來港上市共發售4,332.48萬股H股,並已引入包括Lake Bleu Prime、Orbimed基金、中國結構調整基金及CPE Fund等11名基石投資者,合共認購近1,376萬股;其中9%公開發售獲309倍超購,已啟動回撥機制佔比增至36%,認購一手籤率僅5%;股份以招股範圍(133-151元)上限定價,料集資淨額約62.86億元,主要用作提高集團於蘇州設施服務能力、增強集團於美國業務以迎合客戶日益增長對Biomere所提供服務需求、用於在廣州及重慶建設新設施、拓寬藥物研發價值鏈上綜合服務範圍及拓展海外佈局策略等。上市獨家保薦人中信証券。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.